Related to Oncodesign, Ipsen Seal Potentially $149M LRRK2 Inhibitor Parkinson Disease Deal

• Key to Parkinson’s Pathology May Lie in Cell-to-Cell Transmission of Alpha-Synuclein
  
• Santhera Picks Up Juvantia to Secure Full Rights to Candidate for Treating Parkinson’s
  
• Biovail Pays Santhera $8M Up Front for North American Rights to Parkinson’s Therapy
  
• Acadia Crashes with Negative Results from Phase III Antipsychosis Candidate
  
• Spirogen Receives About $24M for Clinical-Stage Anticancer Drug and Reacquires Development Rights
  
• Nine European Countries Sanction Six-Month Formulation of Debiopharm’s Prostate Cancer Medication
  
• Boehringer Ingelheim Receives EC Clearance for Once-Daily Version of Parkinson's Therapy
  
• ArmaGen Chooses PacificGMP to Manufacture Fusion Protein for Phase I Trial in Stroke and Parkinson’s
  
• Gene for Gaucher’s Increases Risk for Parkinson's
  
• SurModics and NuPathe Ally to Develop Parkinson's Treatment
  
• French Authorities Approve Six-Month Formulation of Debiopharm and Ipsen’s Prostate Cancer Drug
  
• Researchers Implicate Common Genetic Variants Involved in Parkinson’s Progression
  
• Newron Raises CHF 7.9M to Help Progress Clinical Trials and Pipeline Development
  
• Merck & Co. Extends Research Arrangement with Addex for One More Year
  
• Scientists Claim Short Amyloid Fibers Are More Toxic than Their Longer Counterparts
  
• Scientists Associate Modified Form of Protein with Three Neurodegenerative Diseases
  
• PDx Obtains NINDS Grant to Uncover Causative Genes for Parkinson Disease
  
• Biovail Acquires U.S. and Canadian Rights to Kyowa Hakko’s Parkinson Disease Drug Candidate
  
• QR Pharma Establishes Academic Partnership to Evaluate Lead AD Candidate against Parkinson Disease
  
• Biovail and MedGenesis Receive $2.1M Grant for Parkinson Disease Trials